2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2731 Real-world treatment patterns, CAR-T utilization and clinical outcomes in patients with diffuse large B-cell lymphoma: An electronic health records analysis

Mazyar Shadman, MD, MPH, Hrishikesh Kale2, Jessica Maitland, MSc3, Elizabeth Hore4, Dominic Pilon, MA5, François Laliberté6, Alex Bokun7
1 Fred Hutch Cancer Center & University of Washington, Seattle, Washington, United States
2 Johnson & Johnson, Raritan, New Jersey, United States
3 Analysis Group ULC, Toronto, Ontario, Canada
4 Analysis Group ULC, Toronto, Ontario, Canada
5 Analysis Group ULC, Montreal, Quebec, Canada
6 Analysis Group ULC, Montreal, Quebec, Canada
7 Johnson & Johnson, Raritan, New Jersey, United States

Introduction:

Approximately 30%–40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapsed or refractory disease following first line (1L) therapy and patients with primary refractory disease have historically had particularly poor outcomes. Chimeric antigen receptor T-cell (CAR-T) therapies have improved outcomes for patients with primary refractory disease in clinical trial settings and are increasingly used in routine practice; however, there are limited contemporary real-world data describing CAR-T utilization, treatment sequencing, and clinical outcomes in this population. Therefore, this study aimed to describe patient characteristics and treatment patterns among a real-world cohort of patients with DLBCL, including clinical outcomes among those with primary refractory or early relapse disease.

Methods:

This retrospective cohort study used electronic health record data from the Cancer Outcomes Tracking and Analysis (COTA) database (6/1/2017–8/31/2025) and included patients with DLBCL who initiated ≥1 line of therapy (LOT), with LOT information derived using a proprietary algorithm designed by COTA. Patient demographics were assessed at DLBCL diagnosis, and treatment patterns, including CAR-T utilization, were described by LOT. Patients with primary refractory or early relapse disease, defined as disease progression or relapse within 16 months of 1L initiation, who initiated a subsequent LOT were identified. These patients were grouped according to receipt of CAR-T within 180 days of first progression or relapse. For patients receiving CAR-T, the index date was the date of CAR-T initiation; for those not receiving CAR-T, the index date was the date of initiation of the first LOT post-progression. Progression-free survival (PFS) and overall survival (OS) were described from the index date using Kaplan-Meier analyses with follow-up time censored at the initiation of a subsequent LOT (PFS only), clinical trial enrollment, or end of data availability. Analyses were performed descriptively, with no formal statistical comparisons between patients receiving or not receiving CAR-T.

Results:

The cohort included 3,119 patients with DLBCL who initiated 1L (median age: 66 years; 56% male; 63% White; 65% received care in community practice settings). The most common regimens by LOT were R-CHOP in 1L (71%), chemoimmunotherapy in 2L (40%), and CAR-T in 3L (34%). Overall, 209 (7%) patients received CAR-T, of whom 19%, 53% and 28% initiated CAR-T in 2L, 3L and 4L+, respectively. Among all patients who received CAR-T, over a median follow-up of 12 months post-infusion, 42 (20%) received ≥1 subsequent LOT. The most common post-CAR-T regimens were chemoimmunotherapy, immunotherapy, and polatuzumab-based therapy, which were each received by 19% of patients with a subsequent LOT after CAR-T, while 17% of patients received a bispecific antibody.

Among 471 patients identified with primary refractory or early relapse disease, 135 (29%) received CAR-T within 180 days of first progression or relapse. PFS and OS rates were descriptively higher among patients receiving CAR-T than those not receiving CAR-T at all time points post-index. Estimated PFS rates among patients receiving CAR-T (median follow-up: 8 months) at 6, 12, and 24 months post-index were 62%, 59%, and 51%, respectively; corresponding estimates among patients not receiving CAR-T (median follow-up post-index: 4 months) were 36%, 21%, and 15%. Estimated OS rates among patients receiving CAR-T (median follow-up: 11 months) at 6, 12, and 24 months post-index were 84%, 71%, and 62%, respectively; corresponding estimates among patients not receiving CAR-T (median follow-up: 7 months) were 67%, 45%, and 32%.

Conclusion:

In this real-world study, patients with primary refractory or early relapse DLBCL who received CAR-T had descriptively higher PFS and OS than those not receiving CAR-T. However, fewer than one-third of patients with primary refractory or early relapse DLBCL received CAR-T, with heterogenous post-CAR-T treatment patterns. Despite improved outcomes in patients receiving CAR-T, a substantial proportion of patients experienced disease progression or death. These findings highlight a potential gap in CAR-T utilization and an ongoing need for more effective therapies, including in the post-CAR-T setting.
Mazyar Shadman, MD, MPH: Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current equity holder in private company; Janssen - Research Funding; AstraZeneca - Research Funding; Sana Biotechnology - Research Funding; Nurix - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Morphosys/Incyte - Research Funding; AbbVie - Research Funding; Beigene - Research Funding; Genmab - Research Funding; Incyte - Research Funding; Vincerx - Research Funding; Mustang Bio - Research Funding; Merck - Research Funding; AstraZeneca - Research Funding; BeOne Medicines - Research Funding; Legend Bio - Research Funding; AbbVie - Research Funding; Genetech - Research Funding; Genmab - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Ascentage Pharma - Consultancy (Includes expert testimony); Mustang Bio - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony); Legend Bio - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Kite, A Gilead company - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Morphosys/Incyte - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); Fate therapeutics - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)